Normotensive patients at intermediate risk of CV disease do not benefit from ARB + HCTZ (HOPE-3)

Normotensive patients at intermediate risk of CV disease do not benefit from ARB + HCTZ (HOPE-3) is a topic covered in the EE+ POEM Archive.

To view the entire topic, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:

Evidence Central

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Normotensive patients at intermediate risk of CV disease do not benefit from ARB + HCTZ (HOPE-3) ID - 1314047 ED - Barry,Henry, ED - Ebell,Mark H, ED - Shaughnessy,Allen F, ED - Slawson,David C, BT - EE+ POEM Archive UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314047/all/Normotensive_patients_at_intermediate_risk_of_CV_disease_do_not_benefit_from_ARB_+_HCTZ__HOPE_3_ PB - John Wiley & Sons DB - Evidence Central DP - Unbound Medicine ER -